{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated due to single participant in the arm.","groupId":"OG000","spread":"NA","value":"-0.2"},{"groupId":"OG001","spread":"1.11","value":"0.8"},{"groupId":"OG002","spread":"29.46","value":"-1.1"},{"comment":"Standard deviation was not calculated due to single participant in the arm.","groupId":"OG003","spread":"NA","value":"-28.8"},{"groupId":"OG004","spread":"31.06","value":"-31.0"},{"comment":"Standard deviation was not calculated due to single participant in the arm.","groupId":"OG005","spread":"NA","value":"-56.5"},{"groupId":"OG006","spread":"28.67","value":"-22.2"},{"comment":"Standard deviation was not calculated due to single participant in the arm.","groupId":"OG007","spread":"NA","value":"-79.9"},{"groupId":"OG008","spread":"4.16","value":"-61.8"},{"groupId":"OG009","spread":"22.27","value":"-14.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"title":"Tumor Sample"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.14","value":"-50.8"},{"groupId":"OG001","spread":"40.22","value":"-66.1"},{"groupId":"OG002","spread":"27.33","value":"-35.2"},{"groupId":"OG003","spread":"22.02","value":"-34.7"},{"groupId":"OG004","spread":"16.56","value":"-42.5"},{"groupId":"OG005","spread":"13.67","value":"-43.0"},{"groupId":"OG006","spread":"9.92","value":"-40.1"},{"groupId":"OG007","spread":"21.04","value":"-40.4"},{"groupId":"OG008","spread":"12.98","value":"-39.2"},{"groupId":"OG009","spread":"18.71","value":"-32.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"11"}],"units":"Participants"}],"title":"Blood Sample"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"}],"units":"Participants"}],"description":"Assessment of Pharmacodynamic (PD) effects of LTT462 in tumor, pre- and post- treatment tumor biopsies were examined for expression of DUSP6. For assessment of PD effects in blood, levels of DUSP6 were measured in blood samples.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 twice daily (BID) as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"MEAN","populationDescription":"The full analysis set included all participants who had received at least one dose of LTT462.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1, 2, 3, 15 and 16","title":"Changes From Baseline in Relative Quantity (RQ) of Dual Specificity Phosphatase 6 (DUSP6) in Tumor Tissue and in Blood","type":"SECONDARY","unitOfMeasure":"Ratio"}